Zydus Lifesciences Limited — Updates, 11-08-2025: Press Release

Zydus Lifesciences received USFDA final approval for its Diltiazem Hydrochloride Tablets (30, 60, 90, 120 mg). This medication, a calcium-channel blocker for angina management, represents a US market opportunity with annual sales of USD 13.9 million (~115.4 Cr). Production will occur at Zydus's Baddi facility. This approval boosts Zydus's US portfolio, bringing their total USFDA approvals to 423 and strengthening their market presence.